COVID-19 Central Research Database
cprnii.png

找到 461 項

網頁(9)

  • Contact Us | Corona ResearchGate

    Contact Us Thanks for submitting! Submit Corporate Headquarter ​ IEEARC Tech SSCBS Innovation and Incubation Foundation (SIIF) Dr. K.N. Katju Marg Rohini Sector 16 Govt. of NCT, Delhi -110089 ​ Write to us contact@ieearc.com ​

  • About Us | Corona ResearchGate

    About Us Hear It From Me Corona ResearchGate is a scientific community for the research of Novel Coronavirus e.g. Covid-19. A unique platform to discover new ideas, scientific publications, current research from all across the world. Dedicated to science and research where you can connect, collaborate and work together. Sign Up/Login

瀏覽全部

論壇文章(452)

  • Omicron blindspots: why it’s hard to track coronavirus variants

    Researchers are racing to detect Omicron, the latest SARS-CoV-2 variant of concern, by sequencing the genomes of coronaviruses infecting people. But surveillance through genomic sequencing can be slow and patchy, complicating the picture of how and where Omicron spreads. One positive development is that researchers are sequencing more SARS-CoV-2 genomes than ever before. This is what enabled them to notice Omicron relatively swiftly. Last April — about 16 months into the pandemic — an online database belonging to the GISAID data-science initiative contained one million SARS-CoV-2 genomic sequences. Since then, researchers have submitted another five million sequences to GISAID in about eight months — a nearly tenfold rate increase (see ‘Genome explosion’). “We are in much better shape to find Omicron or any other emerging variant now,” says Kelly Wroblewski, director of infectious diseases at the Association of Public Health Laboratories in Silver Spring, Maryland All of these studies are evolving daily as new Omicron sequences pour in from around the world. A hint of how fast this field is moving can be seen in the rapid rise in genomes reported after the World Health Organization named Omicron a variant of concern on 26 November. Soon after the agency’s announcement, 15 countries submitted 187 genomic sequences belonging to Omicron to GISAID. By 14 December, 55 countries had shared 4,265 Omicron sequences. The figures are on course to balloon further — but Luo warns that’s not necessarily representative of how fast the variant is spreading. Many testing centres are preferentially sequencing samples after a simple, fast genotyping test picks up a possible signal for Omicron — a particular amino acid in the gene for its spike protein. As a result, Omicron might be overrepresented among SARS-CoV-2 genome sequences right now. Genomic information is biased and messy in so many ways, Luo says. “We have to be careful about what we take away from any one source of data.” Reference & source information: https://www.nature.com/ Read more on:

  • Potential effects of curcumin in the treatment of COVID-19 infection

    The main clinical manifestation of COVID-19 is the presence of respiratory symptoms, but some patients develop severe cardiovascular and renal complications. There is an urgency to understand the mechanism by which this virus causes complications so as to develop treatment options. Curcumin, a natural polyphenolic compound, could be a potential treatment option for patients with coronavirus disease. In this study, we review some of the potential effects of curcumin such as inhibiting the entry of virus to the cell, inhibiting encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. This review provides a basis for further research and development of clinical applications of curcumin for the treatment of newly emerged SARS-CoV-2. CONCLUSION AND CHALLENGES In this review, we have attempted an overview of the potential antiviral effects of curcumin that can be helpful for researchers to further investigate the potency of curcumin against the new emerging SARSCoV-2 infection. The ability of curcumin to modulate a wide range of molecular targets makes it a suitable candidate for the management of coronavirus infection. Curcumin may have beneficial effects against COVID-19 infection via its ability to modulate the various molecular targets that contribute to the attachment and internalization of SARS-CoV-2 in many organs, including the liver, cardiovascular system, and kidney. Curcumin could also modulate cellular signaling pathways such as inflammation, apoptosis, and RNA replication. Curcumin may also suppress pulmonary edema and fibrosis-associated pathways in COVID-19 infection. Despite the potential beneficial effects and safety profile of curcumin against various diseases, the limited bioavailability of this turmericderived compound, especially via oral administration may be a problematic issue (Anand, Kunnumakkara, Newman, & Aggarwal, 2007). Yang et al. demonstrated that intravenous administration of curcumin (10 mg/kg) resulted in better bioavailability in comparison to oral administration with a higher dose (500 mg/kg) (K. Y. Yang, Lin, Tseng, Wang, & Tsai, 2007). Several clinical trials have shown that the issue regarding the bioavailability of curcumin can be mitigated by administering higher concentrations within non-toxic limits (Kunnumakkara et al., 2019). In addition, many studies have suggested various ways to improve the bioavailability of curcumin such as manipulation and encapsulation of curcumin into micelles, liposomes, phospholipid complexes, exosomes, or polymeric nanocarrier formulation and also utilization of curcumin in combination with cellulosic derivatives, natural antioxidants, and a hydrophilic carrier (Jäger et al., 2014; Moballegh Nasery et al., 2020). Moreover, several studies have reported the synergistic therapeutic effects of curcumin in combination with other natural or synthetic compounds (Singh et al., 2013). Overall, the welldocumented anti-inflammatory and immunomodulatory effects of curcumin along with the evidence on the anti-fibrotic and pulmonoprotective effects of this phytochemical on the lung tissue make it a promising candidate for the treatment of COVID-19. Since curcumin is known to have strong inhibitory effects on NF-κB and several pro-inflammatory cytokines, it can be particularly helpful as an adjunct in reversing the fatal cytokine storm that occurs in serious cases of COVID-19. 6 ZAHEDIPOUR ET AL. To sum up, this review shows that curcumin as an antiviral and anti-inflammatory agent can be helpful for both prevention and treatment of new emerging coronavirus. However, well-designed clinical trials are needed to demonstrate the potential efficacy of curcumin against SARS-CoV-2 infection and its ensuing complications. Reference & Source Information: https://onlinelibrary.wiley.com/ Read more on :

  • Vaccine For Coronavirus Likely to be Available by September, Says Oxford Expert Sarah Gilbert

    Professor Sarah Gilbert, an expert of mediconology at the University of Oxford, said she is confident of a vaccine for novel coronavirus being available by September this year. Her claims comes in contradiction of most pharmaceutical wizards predicting an 18-month time frame to find either a vaccine or a cure to the COVID-19 disease. COVID-19 Ten Times Worse Than Swine Flu, Vaccine Needed to Fully Halt Disease: WHO.Londo: Professor Sarah Gilbert, an expert of mediconology at the University of Oxford, said she is confident of a vaccine for novel coronavirus being available by September this year. Her claims comes in contradiction of most pharmaceutical wizards predicting an 18-month time frame to find either a vaccine or a cure to the COVID-19 disease. COVID-19 Ten Times Worse Than Swine Flu, Vaccine Needed to Fully Halt Disease: WHO. Gilbert, while speaking to BBC Radio on Monday, said trials are being conducted across the world at an "unprecedented rate". In the University of Oxford as well, the process to screen over 500 volunteers - aged between 18 to 55 - for the ChAdOx1 nCoV-19 vaccine has been expedited, she said. The manufacturers should be ready to produce the vaccine in bulk, she said, adding that billions across the globe would have to be vaccinated against the disease. The process to initiate manufacturing should not be kept on hold till the vaccine is confirmed to be successful, the professor added. "We need to start manufacturing large amounts of the vaccine. It is not uncommon for companies to start manufacturing a new vaccine before they really know for certain it works”, she told the radio channel during the morning show. The Oxford team, which was successful with its rapid vaccine response tests for Ebola in 2014, is hopeful of repeating the success with its coronavirus vaccine trials. The clinical tests are expected to begin next week, Gilbert said. She had last week told a leading magazine that her team is "80 percent sure" of developing the vaccine. Globally, the COVID-19 pandemic infected more than 1,900,000 persons by the time this report was published. The death toll climbed to 118,497. The worst-affected is the United States, where over 600,000 are infected and the death toll has crossed the 23,000-mark. Italy and Spain have recorded over 20,000 and more than 17,000 deaths, respectively. Source www.nytimes.com

瀏覽全部